EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease

Ahmed M Abdelaziz, Mustafa M Shokr

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.118276 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Ahmed M Abdelaziz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish 45511, Egypt. Electronic address: ahmed.abdela…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms, T-Lymphocytes, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have transformed cancer treatment; however, resistance, on-target toxicity, and limited efficacy in autoimmune disorders have motivated next-generation immunotherapies. T cell engagers (TCEs) redirect cytotoxic T cells to kill pathogenic cells independently of MHC restriction, whereas antibody-drug conjugates (ADCs) deliver potent payloads directly into target cells via receptor-mediated internalization. This review synthesizes preclinical and clinical data on TCEs and ADCs in oncology and immune-mediated inflammatory disorders (IMIDs). The CD47/SIRPα innate immune checkpoint is briefly examined as a case study in next-generation immunopharmacology, with agents like evorpacept and BYON4228 showing encouraging objective response rates (50% ORR) in non-hodgkin lymphoma when combined with rituximab, with next-generation designs reducing hematologic toxicity. Recent compassionate use findings in autoimmunity demonstrate that CD19 × CD3 TCE (blinatumomab) and (B-cell maturation antigen) BCMA × CD3 TCE (teclistamab) elicit rapid clinical improvement in refractory antisynthetase syndrome and systemic sclerosis, accompanied by cytokine release syndrome (CRS) (grade 3 in 40% and 100% of patients, respectively) and no neurotoxicity. In engineered TCEs with attenuated CD3 affinity, grade 1-2 CRS occurs in < 20% of patients. Beyond cell-depleting strategies, bispecific antibodies targeting OX40L/TNFα and anti-TL1A antibodies are advancing in hidradenitis suppurativa and rheumatic diseases. Conversely, ADC strategies have yielded mixed results; an anti-TNF-glucocorticoid receptor modulator ADC failed to outperform adalimumab in a phase 2b trial. Safety profiles differ: TCEs predominantly cause cytokine release syndrome, whereas ADCs pose off-target payload toxicity risks. Emerging dual-targeting TCEs, half-life-extended formats, and rational combinations illustrate key immunopharmacological principles that may broaden the therapeutic landscape for cancer and autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesNeoplasmsT-LymphocytesImmunoconjugatesImmune Checkpoint InhibitorsHumansAnimalsImmunotherapy

Stichwörter der Autor:innen

Antibody-drug conjugateAutoimmune diseaseBispecific antibodyCAR-TCD47/SIRPαCancer immunotherapyCytokine release syndromeT cell engager

Substanzen

ImmunoconjugatesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish 45511, Egypt. Electronic address: ahmed.abdelaziz@su.edu.eg.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University - Arish Branch, Arish 45511, Egypt. Electronic address: mostafa.mohsen@su.edu.eg.

Zitieren

APA

Abdelaziz, A. M., & Shokr, M. M. (2026). Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118276

Vancouver

Abdelaziz AM, Shokr MM. Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118276

BibTeX
@article{Abdelaziz2026,
  author = {Abdelaziz, Ahmed M and Shokr, Mustafa M},
  title = {Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.118276}
}
Kostenlos starten →